TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.

MLA

Regierer, Anne Constanze, et al. “TNFi Is Associated with Positive Outcome, but JAKi and Rituximab Are Associated with Negative Outcome of SARS-CoV-2 Infection in Patients with RMD.” RMD Open, vol. 7, no. 3, Dec. 2021, pp. 1–9. EBSCOhost, https://doi.org/10.1136/rmdopen-2021-001896.

APA

Regierer, A. C., Hasseli, R., Schäfer, M., Hoyer, B. F., Krause, A., Lorenz, H.-M., Pfeil, A., Richter, J., Schmeiser, T., Schulze-Koops, H., Strangfeld, A., Voll, R. E., Specker, C., & Mueller-Ladner, U. (2021). TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD Open, 7(3), 1–9. https://doi.org/10.1136/rmdopen-2021-001896

Chicago

Regierer, Anne Constanze, Rebecca Hasseli, Martin Schäfer, Bimba F. Hoyer, Andreas Krause, Hanns-Martin Lorenz, Alexander Pfeil, et al. 2021. “TNFi Is Associated with Positive Outcome, but JAKi and Rituximab Are Associated with Negative Outcome of SARS-CoV-2 Infection in Patients with RMD.” RMD Open 7 (3): 1–9. doi:10.1136/rmdopen-2021-001896.